Weekly Recap: PM647 IND clearance and Chardan keeps $7 Buy on PRME

Prime Medicine, Inc. (NASDAQ:PRME) jumped about 13% after FDA IND clearance for PM647, clearing the way for U.S. first—in—human Phase 1/2 AATD trials with initial data expected in 2027, while Chardan Capital kept a Buy rating and a $7 target unchanged.Previous Week RecapThis is an AI-generated summ…